



**PRINCESS MARGARET  
GLOBAL PARTNERS' CONSULTATION**

OCTOBER 26TH & 27TH, 2023

**ORIENTATION PACKAGE**

*Attendees and presenters consent to their filming and sound recording. By entering this event site (in person and virtual) you agree to being filmed or photographed which may be used internally or posted externally online.*



## TABLE OF CONTENTS

---

Welcome .....	4
Event Program .....	6
Invited Attendees and Speakers .....	8
International Partners .....	8
International Advisory .....	15
Invited Speakers .....	16
Princess Margaret Cancer Care Network .....	18
Princess Margaret Participants .....	21
Discussion Group Leaders .....	24
Consultation Organizing Team .....	25

# WELCOME



It is with great pleasure and enthusiasm that we extend our warmest welcome to the Princess Margaret Global Partners' Consultation. This momentous event, hosted by the Princess Margaret Global Cancer Program, promises to be a catalyst for meaningful collaboration and progress in the global fight against cancer.

The Global Cancer Program (GCP), established in 2020, has embarked on a remarkable journey thus far. We are delighted to have formed invaluable partnerships with international cancer centers in South America, Europe, Asia, Africa, and the Middle East. These partnerships have blossomed into rich exchanges in the realms of research, education, clinical care, and knowledge mobilization. We have been deeply inspired by the passion and dedication displayed by our partners in advancing the cause of cancer control worldwide.

To date, the partnership exchange has been largely in a virtual format, and initiatives have focused between Princess Margaret and individual institutions. As we continue to evolve and expand, the GCP recognizes the need to build internationally collaborative relationships both between and across institutions. We wish to continue enhancing our global reach and foster bi-directional learning internationally.

It is in this spirit that we created the Global Partners' Consultation, a gathering that aspires to engage leaders in global cancer control, identify common priorities to enhance cancer outcomes, and facilitate networking among our esteemed partners.

We would like to acknowledge that none of this would be possible without you, our partners. We are extremely excited about the wealth of knowledge and expertise that each of you brings to this collaborative table. Cancer control is truly a global issue that requires global collaboration. As such, we are delighted to host attendees from the following institutions:

- A.C. Camargo Cancer Center (Brazil)
- Aga Khan University (Kenya)
- Deutsches Krebsforschungszentrum (Germany)
- Institut Curie (France)
- King Hussein Cancer Centre (Jordan)
- Peter MacCallum Cancer Centre (Australia)
- Tata Memorial Centre (India)
- Vall d'Hebron Institute of Oncology (Spain)
- Clinical Research Malaysia (Malaysia)
- GCP International Advisory (International)
- Princess Margaret National Cancer Care Network (Canada)

Together, we can effect transformative change in the global landscape of cancer control. Thank you for your dedication and commitment to the global fight against cancer. Your presence and contributions will undoubtedly make this event a resounding success.

With warm regards,



A. Keith Stewart, MB, ChB  
VP Cancer, UHN & Director  
Princess Margaret Cancer Centre



Danielle Rodin, MD, MPH, FRCPC  
Director  
Global Cancer Program

# EVENT PROGRAM

## THURSDAY, OCTOBER 26TH

Princess Margaret Cancer Centre, 610 University Ave  
6th floor Bob Bell Auditorium

Time	Event
8:30 - 9:00	Arrival/Coffee
9:00 - 9:15	Opening/Welcome
9:15 - 10:00	Prof. Tim Evans: Global Health - Mobilizing Solidarity Science and Systems
10:00 - 10:50	Partners' Presentations
10:50 - 11:10	Coffee Break
11:10 - 12:00	Partners' Presentations
12:00 - 13:00	Lunch
13:00 - 14:00	Panel - Patient Engagement in Global Cancer Agenda
14:00 - 14:45	Prof. Avi Goldfarb: The Disruptive Economics of Artificial Intelligence in Healthcare
14:45 - 15:45	Panel - Policy, Economics, and Healthcare Delivery Sector
15:45 - 16:00	Coffee Break
16:00 - 17:00	Panel - Philanthropy and Global Cancer Control
17:30 - 18:30	Reception at AGO - 317 Dundas St. W



# FRIDAY, OCTOBER 27TH

Ontario Power Generation (OPG), 700 University Ave.

Time	Event	Location
8:30 - 9:00	Arrival/Coffee	OPG - 4th Floor
9:00 - 10:00	Group Discussion: Clinical Care Innovation	Assignment provided at registration
	Group Discussion: Prevention, Early Detection, and Public Health	
10:00 - 11:15	Poster Showcase with Coffee Break	OPG - 7th Floor
11:15 - 12:15	Group Discussion: Education	Assignment provided at registration
	Group Discussion: Policy, Politics, and Economics of Cancer	
12:15 - 13:15	Lunch	OPG - 7th Floor
13:15 - 14:15	Group Discussion: Research and Innovation	Assignment provided at registration
	Group Discussion: Patient Experience, Supportive and Palliative Care	
14:15 - 15:00	Follow-up from Discussion Groups	OPG
15:00 - 15:45	Open Discussion/Next Steps	OPG
15:45 - 16:15	Coffee Break	OPG
<del>16:15 - 17:00</del>	<del>Hon. Bob Rae: Global Collaboration and Solidarity</del>	<del>PM - Bob Bell Auditorium</del>
17:00	Closing Remarks	OPG

# INVITED ATTENDEES AND SPEAKERS

---

## INTERNATIONAL PARTNERS



### **Victor Piana de Andrade**

Victor Piana de Andrade is the CEO at AC Camargo Cancer Center, São Paulo-Brazil, since April 2021 and worked previously as the Director of Operations, the Medical Director and Surgical Pathologist at the same institution since 2003. He also worked for Memorial Sloan-Kettering Cancer Center (2009-2011) as a Visiting Investigator in Molecular Biology. Victor received his executive education from Insper, São Paulo (2020) and at Harvard Business School (2018).



### **Michael Baumann**

Michael Baumann is Scientific Director and the Chair of the Management Board of the German Cancer Research Center (DKFZ) in Heidelberg. He is also the spokesperson of the German Cancer Consortium (DKTK) and of the National Center for Tumor Diseases (NCT) as well as co-chairman of the Strategy Committee of the German National Decade against Cancer. He is one of the key leaders in the establishment of the National Cancer Prevention Center (NCPC). Michael is a radiation oncologist who pursued the integration of new biological findings with advanced technologies in radiation therapy. He is the recipient of numerous academic awards. He is past president of the German and the European Societies for Radiotherapy and Oncology (DEGRO and ESTRO) and the European Cancer Organization (ECCO) as well as current president of the European Academy of Cancer Sciences (EACS). Moreover, Michael Baumann is editor-in-chief of the journal "Radiotherapy & Oncology".



### **Kate Burbury**

Kate Burbury is an Associate Professor and consultant hematologist, clinician-researcher and Executive Director of Digital and Healthcare Innovations at Peter MacCallum Cancer Centre. Prior to moving to executive role, she was lead clinician for MPN/CML, as well as the haemostasis / thrombosis and peri-procedural optimisation, including prehabilitation; Chair of Senior Medical Staff and Deputy Chief Medical Officer at PeterMac. Professor Burbury is a leading digital health expert which has translated to strategy development, collaborative capacity building, workforce development and a data/digital vehicle pipeline. Her clinical and research program generates collaborations to ensure strategy and focus are directed to key priority health areas, "gaps" in cancer care delivery and translation of scientific developments into the clinic. She has an extensive list of presented abstracts, and has been an invited expert speaker at international scientific meetings.





## **Ros Suzanna Ahmad Bustamam**

Ros Suzanna Ahmad Bustamam is a clinical oncologist by training. She has been serving as the Head of the Department of Radiotherapy and Oncology at Hospital Kuala Lumpur since 2017. In recognition of her expertise and leadership skills, she has also been appointed by the Director General of Health Malaysia as the Head of Service for Radiotherapy and Oncology, Ministry of Health of Malaysia. She plays a crucial role in the development and future direction of radiotherapy and oncology services in Malaysia. Her responsibilities include distribution and infrastructure planning, capacity building and training. Since 2016, Dr. Ros Suzanna has been a key committee member for the National Strategic Plan for Cancer Control Program. Beyond her working hours, she is involved in reaching out to the public for breast cancer awareness campaigns.



## **José Humberto Tavares Guerreiro Fregnani**

José Fregnani serves as the Superintendent of Education and Research at the A.C.Camargo Cancer Center. He is a permanent member of the Scientific Medical Committee and the Assistance, Education, and Research Forum of the A.C.Camargo Cancer Center. He has served as a permanent professor in the Graduate Program of the Pio XII Foundation and the Professional Master's Program of the Antônio Prudente Foundation. Previously, he held leadership positions at the Pio XII Foundation / Barretos Cancer Hospital, including Executive Director of the Education and Research Institute, Scientific Director of the same institute, Coordinator of the Residency Program in Oncological Surgery, Coordinator of the Oncological Gynecology Department, and Coordinator of the Researcher Support Center.



## **Elena Garralda**

Elena Garralda is Codirector of the Vall d'Hebron Institute of Oncology's Clinical Research Program, Group Leader of VHIO's Early Clinical Drug Development Group, and Director of the Research Unit for Molecular Therapy of Cancer (UITM) - CaixaResearch. She graduated with a Medical Degree from Universidad Autónoma de Madrid in 2005 and a master's degree in Molecular Oncology from Centro de Estudios Biosanitarios in 2013. Prof. Garralda's areas of research include targeted agents, early drug development, translational research, immunotherapy, and cellular therapy. Her work includes linking clinical research at VHIO's UITM - CaixaResearch with the different areas of investigation carried out at the institute, such as the molecular analysis of patients' tumors and molecular prescreening, as well as developing novel diagnostic tests to select the best anti-cancer therapies or combinations.



## **Ashlea Gilmore**

Ashlea Gilmore is a Senior Manager, Strategic Partnerships within the Business Ventures division at Peter Mac. She plays a key role in driving forward Peter Mac's Global Partnership Program, which is a catalyst for identifying new collaboration opportunities with key international partners. Ashlea is a graduate of the University of Melbourne and a Board Director of a not-for-profit organization that is dedicated to improving health outcomes for Australian women. Prior to joining Peter Mac, Ashlea advised a number of Australia's leading medical research and life-science organizations and led advocacy campaigns for multi-million business cases and investment proposals. Ashlea has also previously worked in government as a ministerial adviser to the Victorian Minister for Trade and Innovation, where she focused on initiatives related to biotechnology and life-science investment.



## **Jamal Khader**

Jamal Khader is a Full Member Consultant Radiation Oncologist at King Hussein Cancer Centre (KHCC), Head of KHCC Academy for Education & Training and Head of KHCC Training Committee, the past President of Jordan Oncology Society, and the Founder & Director of the Radiation Oncology Residency Program at KHCC. In addition, Dr Khader serves as Senior Faculty Member at The College of European School of Oncology. He conducts research in radiation oncology with special interests in radiotherapy techniques innovation, oncology training and global cancer care. Dr Khader served on the UICC Board of Directors from 2010-2016 and recently has been assigned as Chairman of UICC Technical Fellowship Programs.



## **Asem Mansour**

Asem Mansour has served as CEO and Director General of the King Hussein Cancer Center since April 2012. In this role, he leads a top-performing team of 3600+ professional staff and 450+ physicians that provides the optimum portfolio of services; executing KHCC's vision to provide the highest quality care to cancer patients in Jordan and across the Middle East. Dr. Mansour earned his M.D. from the Vitebsk Medical Institute, School of Medicine. He successfully pursued a fellowship through the Royal College of Radiologists (FRCR- London) and also holds a Master degree of Medical Management (MMM) from Carnegie Mellon University, USA. Dr. Mansour's is past Chairman of the Department of Diagnostic Radiology. Dr. Mansour serves as Executive Chairman to the Jordan Breast Cancer Program and the National Palliative Care Committee.



## Zul Merali

Zul Merali is the Founding Director of the Brain and Mind Institute at the Aga Khan University. He is a neuroscientist and pharmacologist by training (McGill University, University of Ottawa and Wharton). Zul has had over 40 years of academic engagement. He has published over 250 peer-reviewed scientific publications. He has used his proven academic and entrepreneurial ability to add value to forward thinking organizations to help address mental health problems, locally, nationally and globally. His objectives have been to build and/or re-engineer organizations to deliver outstanding results and motivate and encourage others towards positive change.



## Thierry Philip

Thierry Philip is a professor of medical oncology and Chairman of the Board of Directors of Institut Curie. He previously served as President of the Organization of European Cancer Institutes (OEI) and Center Director at the Centre Léon-Bérard in Lyon and RhôneAlpes. He was President of the Fédération Nationale des Centres de Lutte Contre le Cancer (French National Federation of Cancer Centres), which became Unicancer in 2010 and president of the Comité National du Cancer (French National Cancer Committee) and president of the clinical and translational research scientific advisory board at the Fondation Contre le Cancer de Belgique (Belgium Cancer Foundation). Professor Thierry Philip is the author of more than 1000 international scientific publications.



## Alejandro Piris

Alejandro Piris is Chief Scientific Officer and Head of the Scientific Coordination/ Management Area at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona. He coordinates the VHIO Internal Scientific Committee and is evaluator of national and international research Calls. He has completed a Masters in Management of R, D & I in Health Sciences. Previously, he worked as Research Projects Manager in Translational Cancer Drugs Pharma and was senior consultant in Mensor (Research Department). Prof. Piris graduated in Veterinary Science (Complutense University of Madrid) and holds a PhD cum laude in Biochemistry and Molecular Biology (Pasteur Institute and Denis Diderot University, Paris). He has also completed a post-doctoral stay (Juan de la Cierva Program) at the National Center of Biotechnology (Madrid), focused on the design of new viral vaccines.



## Mansoor Saleh

Mansoor Saleh, received his early education in the Aga Khan School system in East Africa, his medical education at the University of Heidelberg in Germany and conducted his doctoral research at the Max Planck Institute for Medical

Research in Heidelberg. He received his training in internal medicine at the Henry Ford Hospital in Detroit Michigan and clinical and translational research training in Hematology & Oncology at the University of Alabama Comprehensive Cancer Center in Birmingham, Alabama where he was tenured Professor of Medicine & Pathology and Director of the First-in-Human Early Drug Development Program. His area of research and clinical focus is “targeted therapy of cancer”. In January 2020, he joined the Aga Khan University in Nairobi, Kenya as the Founding Chair, Department of Hematology - Oncology and Founding Director - AKU, N Cancer Center.



## Dominic Wall

Dominic Wall is Executive Director Business Ventures, leading the organisation’s existing and emerging business ventures programs, as well as leading the partnerships, enterprise and commercialization portfolios. He also oversees the Centres of

Excellence in Cellular Immunotherapy and Theranostics at Peter Mac. He governs Peter Mac’s Pathology services and the associated commercial unit Nexomics which provides specialized accredited medical oncology testing for clinical research. Dominic is also Chief Scientific Officer of Peter Mac’s commercial spin-out Cell Therapies Pty Ltd which he co-founded in 2003. Cell Therapies provides specialized contract manufacturing and testing of cells for human therapy, predominantly in the field of cellular immunotherapy and gene therapy.



## Akhmal Yusof

Akhmal Yusof has led the Clinical Research Malaysia (CRM) as Chief Executive Officer since 2015. CRM is a Malaysia Ministry of Health owned company established in 2012 to promote Sponsored Research in Malaysia. CRM is now accredited

ISO9001:2016 and ISO37001:2015. Dr. Akhmal Yusof is also a member Board of Trustee National Institute of Biotechnology Malaysia. He graduated from the Royal College of Surgeons in Ireland in 1992 and practiced medicine in the public and private hospital for 10 years. He later worked with the American International Assurance in Malaysia as Medical Manager. Later, he led the Medical Department in AstraZeneca for over 13 years. His main forte in the pharmaceutical industry are clinical research management, regulatory affairs, medical and government affairs.



## Gal Markel

Prof. Gal Markel (MD, PhD, MBA) holds the positions of Director of the Davidoff Comprehensive Cancer Center, Founder & Chairman of the Samueli Integrative Cancer Pioneering Institute, and Deputy CEO of Rabin Medical Center. He is a full professor of Cancer Immunology at Tel Aviv University, and a medical oncologist. He has over 140 published papers and 25 patents. Among his most notable achievements is the discovery of CEACAM1 as an immune checkpoint, and pioneering the utilization of fecal microbial transplantations as an immuno-modulator for melanoma patients. He is the founder, CSO, or CMO of five companies, serves on various national boards, and on scientific advisory boards of pharmaceutical companies. He is a highly sought-after international speaker and his contributions have been recognized with numerous awards.



## Dan Oppenheim

Prof. Oppenheim initiated the planning and the establishment of the Davidoff Cancer Center, the first and the only comprehensive cancer center in Israel. He headed the Strategy and Planning of Hospitals Research Unit at the Gertner National Research Center for Health Policy of the Tel Aviv University, and lectures on Strategy and Hospital Planning. Prof. Oppenheim is the founder and chairman of MedicDan, a company that prepares strategic plans and programs for hospitals in Israel and globally. He previously served as the CEO and director general of Rabin Medical Center (RMC), and Herzliya Medical Center. He currently serves as an Assistant to the Dean for Resources Development at the Tel Aviv University School of Medicine, and as President of the International FRMC, promoting and initiating collaboration between RMC and other Medical Centers around the world.



## **Rajendra Badwe**

Prof Rajendra Badwe is a surgeon and oncologist, and Director of the Tata Memorial Centre, a world-renowned cancer institution. He is an international opinion leader in oncology, developing breast cancer care strategies, innovative research, integrating delivery systems, improving quality and cancer management programs and capacity building in cancer care delivery strategy and practice. While Head of Department of Surgical Oncology, he implemented the Clinical Research Secretariat to ensure commitment to research and established the DAE Clinical Trials Centre. He has been conferred Padma Shri National Award by the President of India for the contribution to the field of Medicine in 2013. He received the Lal Bahadur Shastri National Award for Excellence in Public Administration, Academics and Management 2013. He received a Recognition Award for his significant contribution to the Oncology Field from the UAE Cancer Congress and the UICC Reach to Recovery International Medal, UICC.



## **C.S. Pramesh**

Prof. Pramesh is the Professor and Head of Thoracic Surgery and the Director of Tata Memorial Hospital in Mumbai, India. He is the convenor of the National Cancer Grid, a network of over 300 major cancer centers, research institutes, patient groups, and charitable institutions across India. Pramesh is highly committed to reducing inequities in cancer care and making cancer treatment accessible to all geographic regions and strata of society. His primary clinical areas of interest include esophageal and lung cancers and minimally invasive surgery. He serves on the UICC Board of Directors and is the Principal Investigator in several randomized trials on cancer screening, surgical techniques, and neoadjuvant treatment of thoracic cancers. He is also a visiting professor at the Division of Cancer Studies at King's College London and the Institute of Cancer Policy at King's Health Partners.

## INTERNATIONAL ADVISORY



### Felicia Knaul

Felicia Marie Knaul is the Director of the Institute for Advanced Study of the Americas and the Office of Hemispheric and Global Affairs, where she leads the Secretariat of the Hemispheric University Consortium; a Professor at the Leonard M. Miller School of Medicine; and a Full Member of the Cancer Control Program at the Sylvester Comprehensive Cancer Center at the University of Miami. She is a Senior Economist at the Mexican Health Foundation. As a result of her breast cancer experience, Dr. Knaul became the founding President of *Cáncer de Mama: Tómatelo a Pecho*, and published a memoir about her cancer journey. She currently serves as Co-Chair of the Lancet Commission on Cancer and Health Systems and of the Lancet Commission on Gender-based Violence and Maltreatment of Young People. She also founded and co-chaired the Lancet Commission on Global Access to Palliative Care and Pain Relief.



### Patrick Loehrer

Patrick Loehrer is a medical oncologist specializing in gastrointestinal and thymic cancers and director emeritus of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC). He is currently an IU Distinguished Professor, the Joseph W. and Jackie J. Cusick Professor of Oncology, and the Director of the Center for Global Oncology and Health Equity at the IUSCCC. Dr. Loehrer is recipient of numerous awards including the inaugural Allen S. Lichter Visionary Leader Award and the 2023 Humanitarian Award from ASCO. He received his medical degree from Rush Medical College in 1978. He completed his internship and residency at Rush Presbyterian St. Luke's Medical Center and a fellowship in medical oncology at Indiana University. In 1983, he joined the faculty of IU School of Medicine.



### Richard Sullivan

Richard Sullivan FRCS PhD FFPM is Professor of Cancer and Global Health at King's College London and Guy's Comprehensive Cancer Centre. He is Director, Institute of Cancer Policy & Director, Centre for Conflict & Health Research at King's. He is an advisor to the WHO, World Bank, and various international organisations. His global cancer research programs cover cancer systems strengthening, political economy, global cancer surgery particularly virtual reality-enhanced surgical simulation. He also directs research programs on conflict and health with a focus on the Middle East, including Health Security Intelligence, Global Health Security and health systems strengthening in conflict. Richard was formally Clinical Director of Cancer Research UK and Director, of the Council for Emerging National Security Affairs.

## INVITED SPEAKERS



### Tim Evans

Tim Evans joined McGill University in September 2019, as the Inaugural Director and Associate Dean of the School of Population and Global Health (SPGH) and Associate Vice-Principal (Global Policy and Innovation). He joined McGill after a tenure as the Senior Director of the Health, Nutrition and Population Global Practice at the World Bank Group. Tim previously served as Dean of the James P. Grant School of Public Health at BRAC University, Senior Advisor to the BRAC Health Program, Assistant Director General at the WHO, and Director of the Health Equity Theme at the Rockefeller Foundation. At WHO, he led the Commission on Social Determinants of Health and oversaw the production of the annual World Health Report. He has been a co-founder of the Global Alliance on Vaccines and Immunization (GAVI). Tim has been at the forefront of advancing global health equity and health systems delivery for over 20 years.



### Avi Goldfarb

Avi Goldfarb is the Rotman Chair in Artificial Intelligence and Healthcare and a professor of marketing at the Rotman School of Management, University of Toronto. He is Chief Data Scientist of the Creative Destruction Lab, Senior Editor at Marketing Science, and a Research Associate at the National Bureau of Economic Research. He is also a scientific leadership team member at Acceleration Consortium. Prof. Goldfarb's research focuses on the opportunities and challenges of the digital economy. Prof. Goldfarb is also a former Senior Editor at Marketing Science. His work on online advertising won the INFORMS Society of Marketing Science Long Term Impact Award. He testified before the U.S. Senate Judiciary Committee on competition and privacy in digital advertising. His work has been referenced in White House reports, European Commission documents, the New York Times, and the Economist.



### Deborah Maskens

Deb Maskens is a co-founder of both Kidney Cancer Canada and the International Kidney Cancer Coalition. A long-time kidney cancer patient herself, Deb is a frequent speaker at national and international cancer meetings where she provides the patient voice perspective along with sound advocacy knowledge and experience. Deb has worked tirelessly to ensure equal access to high quality care for kidney cancer patients across Canada and internationally. She has served as a Patient Advocate on the U.S.-based National Cancer Institute Renal Task Force. In Canada, she co-leads Can Certainty, a coalition campaign of 35 cancer organizations toward full public coverage of take-home cancer medications. For her role in establishing Kidney Cancer Canada, Deb has been recognized with the Meritorious Service Medal by Canada's Governor General.





## André Picard

André Picard is a health reporter and columnist for The Globe and Mail, where he has been a staff writer since 1987. He is also the author of six bestselling books. André is a two-time winner of the Columns category at Canada's National Newspaper

Awards, and a past winner of the prestigious Michener Award for meritorious public service journalism. He was named Canada's first Public Health Hero by the Canadian Public Health Association, and a Champion of Mental Health by the Canadian Alliance on Mental Illness and Mental Health. He received the Queen Elizabeth II Diamond Jubilee Medal for his dedication to improving healthcare. André is a graduate of the University of Ottawa and Carleton University, and has received honorary doctorates from eight universities, including UBC and the University of Toronto.



## Hon. Bob Rae

Bob Rae is the Ambassador and Permanent Representative of Canada to the United Nations in New York. Before his appointment by the Government of Canada, he served as Canada's special envoy on humanitarian and refugee issues.

The former premier of Ontario and former interim leader of the Liberal Party of Canada, Mr. Rae was elected 11 times to federal and provincial parliaments between 1978 and 2013. He stepped down as a member of Parliament in 2013 to return to legal practice and, in particular, to work with Indigenous communities and continue his work in education, governance and human rights. His passion for social justice dates back to his early days in student politics and community service. Mr. Rae is a privy councillor, a companion of the Order of Canada and a member of the Order of Ontario and has numerous awards and honorary degrees from institutions around the world.



## Lorna Warwick

Lorna Warwick was appointed CEO of the Lymphoma Coalition in December 2018. She had previously been the Coalition's Director of Strategic Communications and Engagement. Lorna has successfully held senior leadership roles in health charities

for more than twenty years and has a diverse background in patient advocacy, mission development, communications, and strategic planning. Her efforts have been focused on haematological cancers since 2003, at both a national and global level. The rich data procured from the biennial Lymphoma Coalition Global Patient Survey on Lymphomas and CLL has allowed Lorna to analyze and report on the global patient experience by subtype, therapy area, geographic area, gender and age.

## PRINCESS MARGARET CANCER CARE NETWORK



### Peter Anglin

Peter Anglin obtained his medical degree from Queens University at Kingston and followed this with clinical fellowships in internal medicine, clinical hematology and oncology. Dr. Anglin's clinical focus has been in haematologic and lymphoid malignancies. He is currently Physician Lead for the Stronach Regional Cancer Centre in Newmarket, Ontario. After pursuing an MBA from the Rotman School of Management at the University of Toronto he has developed an interest in health systems delivery, process redesign in the ambulatory setting, and optimizing drug access for oncology patients.



### Andrea Bezjak

Andrea Bezjak is a Professor in the Departments of Radiation Oncology and Clinical Epidemiology & Health Care Research at the University of Toronto, Canada and staff radiation oncologist at the Princess Margaret Cancer Center, specializing in thoracic malignancies and management of extra-cranial metastatic disease. She has held a number of leadership positions locally and nationally, including being the PM Cancer Program Site Group Leader, the inaugural Addie MacNaughton Chair in Thoracic Radiation Oncology, President of Canadian Association of Radiation Oncology, Chair of Canadian Radiation Oncology Foundation, Chair of the NCIC Clinical Trials Group Quality of Life Committee, and Member of the Board of several international professional societies. She has been a principal investigator of multi-center clinical trials in lung cancer. She is passionate about excellence in clinical care, research and education. In 2021, she was appointed Medical Director of the Princess Margaret Cancer Care Network.

### Alison Martin

Alison Martin completed her internal medicine residency and hematology fellowship at the Schulich School of Medicine and Dentistry. She currently works at the Grand River Regional Cancer Centre as a malignant hematologist and Co-Medical Director for the program. The Hematology Medical Director has a shared responsibility with the Administrative Director of the oncology program for leading the overall delivery of hematology service to patients in a safe and efficient manner, while ensuring both the quality of the service and the careful use of the hospital's resources.



## Jane Martin

Jane is the Vice President of Regional Programs and clinical support services and Regional Vice President, Waterloo Wellington Regional Cancer Program of Ontario Health, Cancer Care Ontario. Jane was appointed Freeport Campus Executive Lead in 2022. As the Regional Vice President, Waterloo Wellington Regional Cancer Program, Jane shapes and champions a vision of cancer care. She leads a team of clinicians and care providers within the hospital to work collaboratively with regional partners to improve cancer services according to strategic objectives set out in the regional and provincial cancer plans. Jane is a registered pharmacist with more than 30 years of healthcare experience in direct care, project management and leadership.



## Beth Snow

Beth Snow graduated from the Grace General Hospital, School of Nursing; in addition, holds a BSc in Nursing from the University of Cardiff and a degree in International Health Care Management from the University of Cumbria. She has worked at Eastern Health, now known as NL Health Services, for 18 years, more than 11 of those with the Provincial Cancer Care Program. She has had the good fortune to hold positions as a front-line registered nurse, Division Manager of Systemic Therapy and Supportive Services of the tertiary and three regional centers, and currently is the Senior Director of the Provincial Cancer Care Program, NL Health Services.



## Terri Stuart-McEwan

Terri Stuart-McEwan is the Vice President, Clinical Programs and Chief Nurse Executive (CNE) and is an Adjunct Lecturer at the Bloomberg School of Nursing at University of Toronto. Over the last 30 years, Terri has been in progressive leadership roles across Canada, including Ontario, Saskatchewan, and Nova Scotia. She also has extensive experience and collaboration with strategic assessment, partnership engagement, and collaboration with programs across Canada and international partnerships. In addition, she has been an Ontario Health Lead for both academic and community hospitals in surgery, oncology, and endoscopy. Terri actively participates in teaching, scholarship, and research with a focus on leadership and implementation science in clinical practice.



## **Teri Stuckless**

Teri Stuckless, graduated from the Faculty of Medicine at Memorial University and completed residency training in radiation oncology at Queen's University. She is an Associate Professor at Memorial University and a practicing radiation oncologist in Cancer Care Program of Newfoundland and Labrador Health Services (NLHS) and specializes in gynecological and gastrointestinal malignancies. She is currently the Clinical Chief of the NLHS provincial Cancer Care Program, and Director in the Office of Learner Well-being and Success in the Faculty of Medicine. She has served as the Division Head of Radiation Oncology, medical advisor to the Department of Health and Community Services of the Government of Newfoundland and Labrador. Her research interests include resource management, survivorship, and well-being.



## **Woodrow Wells**

Woody Wells is the Radiation Medicine Physician Lead for the Central Region of Ontario, based at the Stronach Regional Cancer Centre, at Southlake Regional Health Centre in Newmarket. Prior to the opening of the Stronach Regional Centre, he was an attending radiation oncologist at Princess Margaret. He is an Assistant Professor at the University of Toronto. Dr. Wells clinical interests are in skin cancer and malignant lymphomas. At the Stronach Centre his particular interest is in the culture of the inter-disciplinary workplace as it relates to quality, safety and efficiency. He is the co-chair of the Quality and Utilization Committee of the Stronach Regional Cancer Centre, and has a keen interest in the intersection of technology and workplace culture.

## PRINCESS MARGARET PARTICIPANTS



### Mary Gospodarowicz

Mary Gospodarowicz, professor of radiation oncology, past Chair of Radiation Oncology at the University of Toronto, and past director of the Princess Margaret Cancer Centre has a longstanding interest in clinical research in genitourinary cancers and lymphomas. Her current interests include global cancer control, global access to radiotherapy, and technology innovation. She is currently the Interim Director of the Princess Margaret Global Cancer Program. She is a past president of UICC, where she continues to engage in cancer staging and prognostic factors projects. She participated in the Global Task Force for Cancer Care and Control, co-led the Lancet Oncology Commission on Radiotherapy, and currently co-chairs the Lancet Commission on Cancer and Health Systems and the Lancet Oncology Commission on Cancer in the Commonwealth.



### Danielle Rodin

Danielle Rodin is a radiation oncologist at the Princess Margaret Cancer Centre and an Assistant Professor in the Department of Radiation Oncology at the University of Toronto. She is the Director of the Global Cancer Program at Princess Margaret Cancer Centre and was elected to the Board of Directors for the Union for International Cancer Control (UICC) in Geneva. Her clinical interests are in breast cancer and hematologic malignancies. She is a health services researcher, with interests in health technology assessment, global health systems, and large database analyses of cost and quality in cancer care. Dr. Rodin was the 2017-2018 Canadian Harkness Fellow in Health Care Policy and Practice in the Department of Health Policy and Management at the Harvard T. H. Chan School of Public Health.



### Keith Stewart

Keith Stewart is Director of the Princess Margaret Cancer Centre and Vice President Cancer at University Health Network (UHN). He is the Richard H. Clark Chair in Cancer Medicine and a Professor in the Department of Medicine at the University of Toronto. Dr. Stewart is also the Regional Vice President, Ontario Health, Toronto Central South Cancer Program. In these roles he oversees all aspects of cancer care, research and education across UHN and has regional responsibility for cancer programs in central Toronto. Dr. Stewart's own research focuses on multiple myeloma. He has a laboratory and clinical research program in genomics and biology of myeloma and has led numerous clinical trials of novel therapeutics for this disease. Dr. Stewart has served on the advisory and medical or scientific boards of many private and public institutions, and is currently a non-executive board member of Genomics England.



## **Miyo Yamashita**

Miyo Yamashita is the President and CEO of The Princess Margaret Cancer Foundation. Prior to that, Miyo worked in public healthcare and risk management before moving to corporate Canada, where she has held senior leadership roles in management consulting, banking, and IT. She has led large enterprise transformation initiatives and major operations as the Global Chief Privacy Officer and head of digital compliance for TD Bank Group, and as the Chief Strategy Officer for MindBridge Ai. An entrepreneur, Miyo founded her own consulting company, which was later acquired by Deloitte Canada. At Deloitte, Miyo served on the Executive Committee of the Canadian and Chilean firms. She also served on Deloitte's global board of directors, the first woman from a minority group to do so. In 2017, she was named one of Canada's Top 100 Most Powerful Women by the Women's Executive Network.



## **Bradly Wouters**

Bradly Wouters is an internationally recognized leader and cancer researcher. He became Executive Vice President of Science and Research at UHN in 2016 and prior to that served as the Interim Director of Research at the Princess Margaret Cancer Centre since 2014. He joined UHN as Senior Scientist and Director of the Princess Margaret Hypoxia Program, and has held faculty appointments at the University of Toronto in the Departments of Medical Biophysics and Radiation Oncology. Prior to joining UHN, Dr. Wouters was Professor and Head of Experimental Radiation Oncology at Maastricht University in the Netherlands. As EVP of Science and Research, Dr. Wouters is focused on creating an environment that incentivizes, facilitates, and rewards excellence in basic, translational, and clinical research across all elements of UHN.



## **Bob Bell**

Bob Bell served as Ontario's Deputy Minister of Health from 2014 to 2018. Prior to this role, he worked as President and Chief Executive Officer of University Health Network (UHN) for nine years. He was previously the Chief Operating Officer at

Princess Margaret Hospital, the Chair of Cancer Care Ontario's Clinical Council and the Cancer Quality Council of Ontario. Bell practiced Orthopaedic Oncology Surgery at Mount Sinai Hospital and Princess Margaret Hospital and is a Professor Emeritus in the Department of Surgery at University of Toronto. Dr. Bell is a Fellow of the Royal College of Physicians and Surgeons of Canada, the American College of Surgeons and an Honorary Fellow of the Royal College of Surgeons of Edinburgh. Today he provides advice to a number of private and public organizations, and serves as a director on not-for-profit and corporate boards. He has published three novels, with all proceeds from these books benefiting UHN foundations.



## **John Kuruvilla**

John Kuruvilla is a Professor of Medicine at the University of Toronto and a hematologist in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre (PM) in Toronto. He is a member of the Lymphoma, Autologous


Transplant and Immune Effector Cell Therapy programs. He is also the Co-Director of the High Definition Therapeutics Strategic Pillar for PM. Dr. Kuruvilla's research interest is the development of novel therapeutics in lymphoid malignancies and incorporating translational research into clinical trials. He is the Lymphoma Co-Chair for the Canadian Cancer Trials Group as well as the Chair of the Scientific Advisory Board of Lymphoma Canada.

## DISCUSSION GROUP LEADERS



### Monika Krzyzanowska

Monika is co-chair of the Clinical Practice Committee at Princess Margaret. She also serves as the Medical Lead and chair of the Cancer Quality Program, and has interest in advancing the science and practice of quality in cancer care.



### Rebecca Wong

Rebecca Wong is the Director of the Clinical Trials Program for Radiation Medicine at the Princess Margaret. Her clinical and research interests are aimed at improving the outcomes of patients with gastroesophageal and metastatic cancer.



### Beverley Essue

Beverley Essue is an Associate Professor of Global Health at the Dalla Lana School of Public Health, University of Toronto. She is a health economist and leads research on advancing equity, including gender equity, across global health systems.



### Camilla Zimmermann

Camilla Zimmermann is Head of the Division of Palliative Care at Princess Margaret. She is internationally known for her research on palliative and supportive care, particularly in early integration of palliative care for patients with cancer.



### Michael Milosevic

Michael Milosevic is Vice-Chair of Research in the Department of Radiation Oncology at Princess Margaret. His research focuses primarily on MR-guided adaptive radiotherapy and hypoxia-dependent radiation treatment resistance.



### Gary Rodin

Gary Rodin is the Director of the Cancer Experience Program, a comprehensive program to support the interconnected well-being of patients, families, staff, and trainees.. He is a leading expert in the psychiatric and psychosocial aspects of cancer



### Meredith Giuliani

Meredith Giuliani is the Medical Director of Education for the Princess Margaret Cancer Centre. Her research interests include the influence of globalization on education with a focus on curriculum design and implementation.



# CONSULTATION ORGANIZING TEAM



**Mary Gospodarowicz**

Interim Director  
Global Cancer Program



**Calvin D'Souza**

Manager  
Strategy and Transformation



**Laurice Karkaby**

Manager  
Global Cancer Program



**Jacqueline Hutton**

Education Coordinator  
Global Cancer Program




**Arleigh Dean**

Project Coordinator  
Global Cancer Program



**Renie Kee**

Project Coordinator  
Strategy and Transformation



**Judy Zhu**

Associate  
Strategy and Planning

